CSL Limited (ASX: CSL)
Australia
· Delayed Price · Currency is AUD
280.10
+1.78 (0.64%)
May 31, 2024, 4:10 PM AEST
CSL Limited Revenue
CSL Limited had revenue of $21.20B USD in the twelve months ending December 31, 2023, with 50.31% growth year-over-year. Revenue in the quarter ending December 31, 2023 was $12.28B USD with 49.51% year-over-year growth. In the fiscal year ending June 30, 2023, CSL Limited had annual revenue of $19.59B USD with 35.36% growth.
Revenue (ttm)
$21.20B
Revenue Growth
+50.31%
P/S Ratio
4.25
Revenue / Employee
$661,103
Employees
32,065
Market Cap
135.36B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2023 | 19.59B | 5.12B | 35.36% |
Jun 30, 2022 | 14.47B | 707.95M | 5.14% |
Jun 30, 2021 | 13.76B | 186.20M | 1.37% |
Jun 30, 2020 | 13.58B | 1.68B | 14.08% |
Jun 30, 2019 | 11.90B | 1.77B | 17.45% |
Jun 30, 2018 | 10.13B | 964.92M | 10.53% |
Jun 30, 2017 | 9.17B | 1.05B | 12.88% |
Jun 30, 2016 | 8.12B | 2.66B | 48.77% |
Jun 30, 2015 | 5.46B | 123.80M | 2.32% |
Jun 30, 2014 | 5.33B | 384.40M | 7.77% |
Jun 30, 2013 | 4.95B | 413.49M | 9.11% |
Jun 30, 2012 | 4.54B | 61.41M | 1.37% |
Jun 30, 2011 | 4.48B | 688.64M | 18.18% |
Jun 30, 2010 | 3.79B | 56.37M | 1.51% |
Jun 30, 2009 | 3.73B | 327.68M | 9.63% |
Jun 30, 2008 | 3.40B | 712.07M | 26.46% |
Jun 30, 2007 | 2.69B | 576.72M | 27.28% |
Jun 30, 2006 | 2.11B | 17.21M | 0.82% |
Jun 30, 2005 | 2.10B | 940.18M | 81.29% |
Jun 30, 2004 | 1.16B | 277.98M | 31.64% |
Jun 30, 2003 | 878.66M | 122.07M | 16.13% |
Jun 30, 2002 | 756.59M | -86.72M | -10.28% |
Jun 30, 2001 | 843.31M | - | - |
Jun 30, 2000 | 0 | - | - |
Jun 30, 1999 | 0 | - | - |
Jun 30, 1998 | 0 | - | - |
Jun 30, 1997 | 318.10M | 37.00M | 13.16% |
Jun 30, 1996 | 281.10M | 30.67M | 12.25% |
Jun 30, 1995 | 250.43M | 57.43M | 29.76% |
Jun 30, 1994 | 193.00M | 25.30M | 15.09% |
Jun 30, 1993 | 167.70M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ResMed Inc. | 6.65B |
Cochlear Limited | 2.18B |
Fisher & Paykel Healthcare Corporation Limited | 1.56B |
Pro Medicus Limited | 142.12M |
Sonic Healthcare Limited | 8.21B |
Ramsay Health Care Limited | 15.96B |
Telix Pharmaceuticals Limited | 502.55M |
Neuren Pharmaceuticals Limited | 231.93M |
CSL Limited News
- 2 days ago - CSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza - PRNewsWire
- 12 days ago - Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine - PRNewsWire
- 12 days ago - Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine - Business Wire
- 4 weeks ago - Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons - PRNewsWire
- 5 weeks ago - CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - PRNewsWire
- 2 months ago - Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure - PRNewsWire
- 2 months ago - CSL Ltd's Dividend Analysis - GuruFocus
- 3 months ago - CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season - PRNewsWire